Baker Danial E
Washington State University, Spokane, WA, USA.
Hosp Pharm. 2017 Nov;52(10):669-674. doi: 10.1177/0018578717733478. Epub 2017 Sep 25.
Each month, subscribers to receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of publishes selected reviews in this column. For more information about , contact Wolters Kluwer customer service at 866-397-3433. The November 2017 monograph topics are Ertugliflozin, Glecaprevir / pibrentasvir, Neratinib, Sofosbuvir, velpatasvir, voxilaprevir and SQ C1 esterase inhibitor. The MUE is on glecaprevir, pibrentasvir.
每月，订阅者会收到5至6篇关于新发布或处于3期临床试验后期阶段药物的详细专题论文。这些专题论文面向药学与治疗学委员会。订阅者还会每月收到1页关于对议程以及药学/护理在职培训有用药物的简要专题论文。每月还会提供一份全面的目标药物利用评估/药物使用评估（DUE/MUE）。订阅后，专题论文可供订阅者在线获取。专题论文可进行定制以满足机构需求。通过合作，[此处原文可能有误，推测是“Through the cooperation of publishers”之类的表述，按照推测修改后翻译为：通过出版商的合作]在本专栏发表精选评论。如需了解更多关于[此处原文可能有误，推测是“关于什么”之类的表述，按照推测修改后翻译为：关于……的更多信息]，请致电866 - 397 - 3433联系威科集团客户服务部。2017年11月的专题论文主题包括恩格列净、格卡瑞韦/哌柏西利、奈拉替尼、索磷布韦、维帕他韦、伏西瑞韦以及SQ C1酯酶抑制剂。MUE针对格卡瑞韦、哌柏西利。
